ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
An ATP7A-Mediated Endogenous Regulation Bio-Clay Enzyme Enables Self-Amplified Copper Accumulation for Immunogenic Pyrop.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Tumor cells maintain abnormal metabolism to support their rapid proliferation, which often compromises the therapeutic outcomes, including pyroptosis. Inhibiting the copper transporter ATPase (ATP7A) effectively disrupts this metabolic balance, yet current exogenous ATP7A inhibition strategies suffer from poor delivery efficiency and low tumor selectivity. Herein, we developed an endogenous regulation strategy to downregulate ATP7A levels using a self-amplifying bio-clay enzyme (Bio-Clayzyme), cupriferous Prussian blue/montmorillonite (CuPB/Mt). Upon tumor cell internalization, CuPB/Mt induces a robust reactive oxygen species (ROS) storm, accompanied by antioxidant depletion, mitochondrial dysfunction, and adenosine triphosphate (ATP) exhaustion. These metabolic disturbances are associated with reduced ATP7A expression, which may subsequently impair ATP7A-mediated copper efflux. The resulting intracellular copper accumulation may further promote ROS amplification, supporting a positive feedback loop among ROS production, ATP7A downregulation, and copper retention. Specifically, the introduction of Mt optimizes the Cu d-band center and strengthens tumor cell adhesion, thereby boosting the multi-enzyme-like catalytic activity and enabling efficient utilization of short-lived ROS. Consequently, CuPB/Mt activates nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3)-dependent pyroptosis and elicits a potent anti-tumor immune response, offering an ATP7A-mediated endogenous regulatory paradigm for self-amplified catalytic therapy and immunogenic pyroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.